A preliminary clinical trial has demonstrated that a combination therapy including zanidatamab, a bispecific antibody targeting HER2, exhibits durable activity in patients with previously treated metastatic hormone receptor-positive (HR+)/HER2+ breast cancer.
 2022 (4).png)
English (US) ·